Search Results - "Eltink, Charlotte"

Pharmacokinetic Properties of Mirabegron, a β3 -Adrenoceptor Agonist: Results From Two Phase I, Randomized, Multiple-Dose Studies in Healthy Young and Elderly Men and Women by Krauwinkel, Walter, MSc, van Dijk, Jan, BSc, Schaddelee, Marloes, PhD, Eltink, Charlotte, MSc, Meijer, John, MSc, Strabach, Grégory, MD, van Marle, Sjoerd, MD, Kerbusch, Virginie, PhD, van Gelderen, Marcel, PhD

“…Abstract Background Mirabegron (YM178) is a β3 -adrenoceptor agonist for the treatment of overactive bladder (OAB). As part of the clinical development program…”
Get full text

Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β₃-adrenoceptor agonist for treatment of overactive bladder by Eltink, Charlotte, Lee, Jennifer, Schaddelee, Marloes, Zhang, Wenhui, Kerbusch, Virginie, Meijer, John, van Marle, Sjoerd, Grunenberg, Nicole, Kowalski, Donna, Drogendijk, Ted, Moy, Selina, Iitsuka, Hiromi, van Gelderen, Marcel, Matsushima, Hiroshi, Sawamoto, Taiji

“…Mirabegron is a potent and selective β3-adrenoceptor agonist in development for treatment of overactive bladder. Mirabegron pharmacokinetics after single…”
Get full text

The pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P‐glycoprotein and CYP3A4 by Groenendaal, Dorien, Strabach, Gregory, Garcia‐Hernandez, Alberto, Kadokura, Takeshi, Heeringa, Marten, Mol, Roelof, Eltink, Charlotte, Onkels, Hartmut

“…WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Darexaban is an oral direct factor Xa inhibitor developed as an antithrombotic for several indications. Several…”
Get full text

Pharmacokinetic Properties of Mirabegron, a [beta]3-Adrenoceptor Agonist: Results From Two Phase I, Randomized, Multiple-Dose Studies in Healthy Young and Elderly Men and Women by Krauwinkel, Walter, van Dijk, Jan, Schaddelee, Marloes, Eltink, Charlotte, Meijer, John, Strabach, Grégory, van Marle, Sjoerd, Kerbusch, Virginie, van Gelderen, Marcel

“…Mirabegron (YM178) is a β3-adrenoceptor agonist for the treatment of overactive bladder (OAB). As part of the clinical development program for mirabegron, 2…”
Get full text

Co-Administration of YM150, An Oral Direct Factor Xa Inhibitor, and Naproxen Does Not Result In Clinically Relevant Changes to the Pharmacodynamic or Pharmacokinetic Profile of Either Agent by Heeringa, Marten, Garcia-Hernandez, Alberto, Kadokura, Takeshi, Meent, Dorien Groenendaal – van de, Strabach, Gregory, Mol, Roelof, Eltink, Charlotte, Heinzerling, Hartmut

“…Abstract 4393 YM150, a potent oral direct factor Xa (FXa) inhibitor, is in development for the prevention of venous thromboembolism after major surgery and of…”
Get full text

The pharmacokinetics of darexaban (YM150), an oral direct factor Xa inhibitor, are not affected by ketoconazole, a strong inhibitor of CYP3A and P-glycoprotein by Groenendaal, Dorien, Strabach, Gregory, Garcia-Hernandez, Alberto, Kadokura, Takeshi, Heeringa, Marten, Mol, Roelof, Eltink, Charlotte, Onkels, Hartmut

“…We investigated the effects of ketoconazole on the pharmacokinetics (PK) of the direct clotting factor Xa inhibitor darexaban (YM150) and its main active…”
Get full text

Single dose pharmacokinetics and absolute bioavailability of mirabegron, a ?3-adrenoceptor agonist for treatment of overactive bladder by Eltink, Charlotte, Lee, Jennifer, Schaddelee, Marloes, Zhang, Wenhui, Kerbusch, Virginie, Meijer, John, Marle, Sjoerd van, Grunenberg, Nicole, Kowalski, Donna, Drogendijk, Ted, Moy, Selina, Iitsuka, Hiromi, Gelderen, Marcel van, Matsushima, Hiroshi, Sawamoto, Taiji

Get full text